Harnessing CRISPR/Cas9 technology in cardiovascular disease

Rezaei, Hamzeh; Khadempar, Saedeh; Farahani, Najmeh; Hosseingholi, Elaheh Zadeh; Hayat, Seyed Mohammad Gheibi; Sathyapalan, Thozhukat; Sahebkar, Amirhosein

doi:10.1016/j.tcm.2019.03.005

Cited by 16 publications

(13 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future developments in the use of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system may allow for even greater improvement of therapeutic strategies [ 91 ]. CRISPR therapies affect gene expression at the level of transcription, a process that precedes the target of both siRNA and AsO therapies.…”

Section: Discussionmentioning

confidence: 99%

RNA-based therapy in the management of lipid disorders: a review

Blom

Marais

Moodley³

et al. 2022

Lipids Health Dis

View full text Add to dashboard Cite

This review focuses on antisense oligonucleotides and small interfering ribonucleic acid therapies approved or under development for the management of lipid disorders. Recent advances in RNA-based therapeutics allow tissue-specific targeting improving safety. Multiple potential target proteins have been identified and RNA-based therapeutics have the potential to significantly improve outcomes for patients with or at risk for atherosclerotic cardiovascular disease. The advantages of RNA-based lipid modifying therapies include the ability to reduce the concentration of almost any target protein highly selectively, allowing for more precise control of metabolic pathways than can often be achieved with small molecule-based drugs. RNA-based lipid modifying therapies also make it possible to reduce the expression of target proteins for which there are no small molecule inhibitors. RNA-based therapies can also reduce pill burden as their administration schedule typically varies from weekly to twice yearly injections. The safety profile of most current RNA-based lipid therapies is acceptable but adverse events associated with various therapies targeting lipid pathways have included injection site reactions, inflammatory reactions, hepatic steatosis and thrombocytopenia. While the body of evidence for these therapies is expanding, clinical experience with these therapies is currently limited in duration and the results of long-term studies are eagerly awaited.

show abstract

Section: Discussionmentioning

confidence: 99%

RNA-based therapy in the management of lipid disorders: a review

Blom

Marais

Moodley³

et al. 2022

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the drawback of iPSC is that the comparison of iPSC lines between different individuals can be confusing due to the difference in epigenetics modifications and its capacities to differentiate into desired specialized cells [65]. Besides, iPSC is also prone to undesired genetic modifications during reprogramming [66].…”

Section: Types Of Cells Used In Crispr/cas9 Applicationsmentioning

confidence: 99%

Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications

Siew

Tang

Kong

et al. 2021

IJMS

View full text Add to dashboard Cite

Atherosclerosis represents one of the major causes of death globally. The high mortality rates and limitations of current therapeutic modalities have urged researchers to explore potential alternative therapies. The clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR/Cas9) system is commonly deployed for investigating the genetic aspects of Atherosclerosis. Besides, advances in CRISPR/Cas system has led to extensive options for researchers to study the pathogenesis of this disease. The recent discovery of Cas9 variants, such as dCas9, Cas9n, and xCas9 have been established for various applications, including single base editing, regulation of gene expression, live-cell imaging, epigenetic modification, and genome landscaping. Meanwhile, other Cas proteins, such as Cas12 and Cas13, are gaining popularity for their applications in nucleic acid detection and single-base DNA/RNA modifications. To date, many studies have utilized the CRISPR/Cas9 system to generate disease models of atherosclerosis and identify potential molecular targets that are associated with atherosclerosis. These studies provided proof-of-concept evidence which have established the feasibility of implementing the CRISPR/Cas system in correcting disease-causing alleles. The CRISPR/Cas system holds great potential to be developed as a targeted treatment for patients who are suffering from atherosclerosis. This review highlights the advances in CRISPR/Cas systems and their applications in establishing pathogenetic and therapeutic role of specific genes in atherosclerosis.

show abstract

“…The CRISPR-associated protein 9 (Cas9) system (CRISPR/Cas9) is a revolutionary gene-editing toolbox that can modify target genes with high precision and that can control various types of genetic diseases in preclinical studies [53][54][55][56]. Due to the collateral nucleic acid cleavage activity of Cas effectors, CRISPR/Cas systems have also been widely used in nucleic acid detection with fluorescent and colorimetric signals [56]. There are mainly two kinds of CRISPR/Cas systems for diagnostics, based on the cutting activity of Cas protein on nucleic acids outside of the gRNA target site: the CRISPR/Cas13a and CRISPR/Cas12a systems.…”

Section: Clustered Regularly Interspaced Short Palindromicmentioning

confidence: 99%

Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community

et al. 2020

View full text Add to dashboard Cite

The World Health Organization (WHO) has declared the outbreak of 2019 novel coronavirus, known as 2019-nCoV, a pandemic, as the coronavirus has now infected over 2.6 million people globally and caused more than 185,000 fatalities as of April 23, 2020. Coronavirus disease 2019 (COVID-19) causes a respiratory illness with symptoms such as dry cough, fever, sudden loss of smell, and, in more severe cases, difficulty breathing. To date, there is no specific vaccine or treatment proven effective against this viral disease. Early and accurate diagnosis of COVID-19 is thus critical to curbing its spread and improving health outcomes. Reverse transcription-polymerase chain reaction (RT-PCR) is commonly used to detect the presence of COVID-19. Other techniques, such as recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), clustered regularly interspaced short palindromic repeats (CRISPR), and microfluidics, have allowed better disease diagnosis. Here, as part of the effort to expand screening capacity, we review advances and challenges in the rapid detection of COVID-19 by targeting nucleic acids, antigens, or antibodies. We also summarize potential treatments and vaccines against COVID-19 and discuss ongoing clinical trials of interventions to reduce viral progression.

show abstract

Harnessing CRISPR/Cas9 technology in cardiovascular disease

Cited by 16 publications

References 50 publications

RNA-based therapy in the management of lipid disorders: a review

RNA-based therapy in the management of lipid disorders: a review

Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications

Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community

Contact Info

Product

Resources

About